L'intérêt à découvert pour Artelo Biosciences donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Artelo Biosciences. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Artelo Biosciences (NASDAQ:ARTL) Stock, Rapport sur les intérêts à découvert

ARTELO BIOSCIENCES INC

Artelo Biosciences

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Artelo Biosciences Inc

Artelo Biosciences Inc Warrants (18/06/2024)

<p>Lake Street  analyst Jaeson Schmidt   maintains BK Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BKTI#AMEX">BKTI</a>) with a Buy and raises the price target from $51 to $55.</p>


News

Price Target

Analyst Ratings

BKTI

Lake Street Maintains Buy on BK Technologies, Raises Price Target to $55

ABBV

AbbVie Announces That EMRELIS Has Been Granted Accelerated Approval By The FDA For The Treatment Of Adult Patients With Locally Advanced Or Metastatic, Non-Squamous Non-Small Cell Lung Cancer With High C-Met Protein Overexpression  Who Have Received A Prior Systemic Therapy

WIIM

RKLB

Rocket Lab shares are trading higher after the company on Wednesday announced the return of its Pioneer spacecraft for Varda Space Industries.

<p>Lake Street  analyst Eric Martinuzzi   maintains Perion Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PERI#NASDAQ">PERI</a>) with a Buy and raises the price target from $10.5 to $13.</p>


PERI

Lake Street Maintains Buy on Perion Network, Raises Price Target to $13

<p>HC Wainwright &amp; Co.  analyst Raghuram Selvaraju   maintains Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) with a Buy and lowers the price target from $20 to $16.</p>


ACRS

HC Wainwright & Co. Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $16

<p>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) will release its quarterly earnings report on Thursday, 2025-05-15. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate NRX Pharmaceuticals to report an <strong>earnings per share</strong> (EPS) of $-0.40.</p>
<p>Investors in NRX Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<p>Here's a look at NRX Pharmaceuticals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td></td>
<td>-0.69</td>
<td>-0.58</td>
<td>-0.37</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.77</td>
<td>-0.15</td>
<td>-0.75</td>
<td>-0.74</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>7.000000000000001%</td>
<td>3.0%</td>
<td>-6.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Performance of NRX Pharmaceuticals Shares</h3>
<p>Shares of NRX Pharmaceuticals were trading at $2.29 as of May 13. Over the last 52-week period, shares are down 37.22%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/NRXP/earnings"><strong>To track all earnings releases for NRX Pharmaceuticals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

NRXP

Uncovering Potential: NRX Pharmaceuticals's Earnings Preview

<p>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-15. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect cbdMD to report an <strong>earnings per share</strong> (EPS) of $-0.36.</p>
<p>cbdMD bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<p>Here's a look at cbdMD's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td></td>
<td>0</td>
<td>-0.62</td>
<td>-0.75</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.22</td>
<td>-0.18</td>
<td>-0.15</td>
<td>-1.35</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-15.0%</td>
<td>-7.000000000000001%</td>
<td>2.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Market Performance of cbdMD's Stock</h3>
<p>Shares of cbdMD were trading at $1.01 as of May 13. Over the last 52-week period, shares are down 82.75%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/YCBD/earnings"><strong>To track all earnings releases for cbdMD visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


YCBD

An Overview of cbdMD's Earnings

<p><strong>Airbnb Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) shares are trending Wednesday following the company's announcement of a <a href="https://www.benzinga.com/general/travel/25/05/45414358/3-airbnb-initiatives-that-could-unleash-growth-opportunities">major platform expansion</a>.</p>
<p><strong>What To Know:</strong> The company introduced Airbnb Services and Airbnb Experiences, along with a redesigned app that integrates bookings for homes, services and activities in a single interface.The updates aim to expand Airbnb's business beyond lodging. </p>
<p>&#8220;Seventeen years ago, we changed the way people travel. More than two billion guests later, Airbnb is synonymous with a place to stay. With the launch of services and experiences, we're changing travel again. Now you can Airbnb more than an Airbnb,&#8221; said <strong>Brian Chesky</strong>, co-founder and CEO of Airbnb.</p>
<p>Airbnb Services includes offerings like in-home chefs, massages, personal training and spa treatments, launching in 260 cities across 10 categories. Airbnb Services will be available at nearly every price, and many services will offer an entry level below $50.</p>
<p>Airbnb Experiences, reimagined with new standards and original content, allows users to book activities hosted by local experts. Experiences range from cultural tours and culinary workshops to sessions hosted by celebrities. The company is launching Experiences in 650 cities globally and plans to add more offerings daily.</p>
<p>Airbnb also unveiled a redesigned app interface featuring real-time itinerary management, a new Explore tab and improved host tools. The company also rebuilt the app for hosts to include everything needed to manage their homes, services or experiences.</p>
<p>The rollout reflects Airbnb's effort to grow its presence in the broader travel and lifestyle market. Chesky described the expansion as a shift from being a platform for booking stays to one offering a complete trip experience. </p>
<p>The new features are available starting this week and hots can access upgrades by enrolling in Airbnb Early Access in the app.</p>
<p><strong>ABNB Price Action</strong>: Airbnb has a 52-week high of $163.93 and a 52-week low of $99.88. Airbnb shares experienced a significant decline of close to 40% from its highs in February to its lows in early April. The stock has rebounded more than 30% off the April lows. Shares were up 0.47% at $138.70 at the time of publication Wednesday, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a></p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/25/05/45406180/only-half-of-sp-500-stocks-joined-the-tariff-relief-rally-time-to-buy-the-laggards">Only Half Of S&amp;P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards?<br /></a></strong></li>
</ul>
<p><em>Image Via Shutterstock.</em></p>


Movers

ABNB

What's Going On With Airbnb Stock Today?

<p>Loop Capital  analyst Timothy Greaves   maintains Porch Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) with a Buy and raises the price target from $6 to $13.</p>


PRCH

Loop Capital Maintains Buy on Porch Group, Raises Price Target to $13

<h3>Gainers</h3>
<ul>
<li><strong>NWTN</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares moved upwards by 66.0% to $1.13 during Wednesday's regular session. The market value of their outstanding shares is at $323.1 million. </li>
<li><strong>Newegg Commerce</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) stock moved upwards by 48.07% to $7.7. The company's market cap stands at $149.9 million. </li>
<li><strong>a.k.a. Brands Holding</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKA#NYSE">AKA</a>) shares increased by 46.78% to $12.77. The company's market cap stands at $136.5 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li><strong>ECD Automotive Design</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) shares rose 40.84% to $0.5. The market value of their outstanding shares is at $17.6 million. </li>
<li><strong>Allurion Technologies</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) stock rose 24.15% to $2.93. The market value of their outstanding shares is at $17.4 million. As per the news, the Q1 earnings report came out today. </li>
<li><strong>Top Win International</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOPW#NASDAQ">TOPW</a>) shares moved upwards by 22.08% to $7.02. The company's market cap stands at $174.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Ruanyun Edai Technology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYET#NASDAQ">RYET</a>) stock decreased by 77.2% to $3.3 during Wednesday's regular session. The company's market cap stands at $111.3 million. </li>
<li><strong>Lobo EV Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) shares declined by 23.58% to $0.94. The company's market cap stands at $8.1 million. </li>
<li><strong>Superior Industries Intl</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>) stock declined by 23.02% to $0.48. The company's market cap stands at $13.8 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li><strong>Boqii Holding</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BQ#AMEX">BQ</a>) shares fell 18.09% to $2.31. The market value of their outstanding shares is at $10.8 million. </li>
<li><strong>GEN Restaurant Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENK#NASDAQ">GENK</a>) shares fell 15.87% to $4.24. The market value of their outstanding shares is at $22.7 million. As per the press release, Q1 earnings came out yesterday. </li>
<li><strong>Global E Online</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) shares declined by 15.29% to $35.91. The company's market cap stands at $6.0 billion. As per the news, the Q1 earnings report came out today.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ALUR

ECDA

GENK

GLBE

LOBO

NEGG

NWTN

RYET

TOPW

12 Consumer Discretionary Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li><strong>Klotho Neurosciences</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock increased by 176.9% to $0.36 during Wednesday's regular session. The company's market cap stands at $10.2 million. </li>
<li><strong>bluebird bio</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) stock moved upwards by 49.89% to $4.96. The market value of their outstanding shares is at $48.5 million. </li>
<li><strong>Septerna</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) stock increased by 41.68% to $9.54. The company's market cap stands at $424.4 million. </li>
<li><strong>Innovative Eyewear</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares increased by 36.11% to $2.69. The company's market cap stands at $8.2 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li><strong>Basel Medical Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) stock rose 32.0% to $5.94. The company's market cap stands at $111.5 million. </li>
<li><strong>Lyra Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) stock rose 24.61% to $0.12. The company's market cap stands at $7.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Polyrizon</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares decreased by 54.4% to $0.01 during Wednesday's regular session. </li>
<li><strong>Accelerate Diagnostics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock decreased by 53.75% to $0.04. The company's market cap stands at $1.0 million. </li>
<li><strong>Biodesix</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock fell 39.83% to $0.22. The market value of their outstanding shares is at $31.3 million. As per the press release, Q1 earnings came out yesterday. </li>
<li><strong>SILO Pharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares fell 23.87% to $0.84. The market value of their outstanding shares is at $3.7 million. The company's, Q1 earnings came out 3 days ago. </li>
<li><strong>Aspire Biopharma Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) stock decreased by 23.56% to $0.25. The market value of their outstanding shares is at $12.1 million. </li>
<li><strong>GRAIL</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) stock fell 22.45% to $33.27. The market value of their outstanding shares is at $1.1 billion. As per the news, the Q1 earnings report came out yesterday.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ASBP

AXDX

BDSX

BLUE

BMGL

GRAL

KLTO

LUCY

LYRA

PLRZ

SEPN

SILO

12 Health Care Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li><strong>Swvl Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWVL#NASDAQ">SWVL</a>) stock moved upwards by 30.6% to $4.15 during Wednesday's regular session. The market value of their outstanding shares is at $44.5 million. </li>
<li><strong>Micropolis Hldgs</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MCRP#AMEX">MCRP</a>) shares rose 21.82% to $2.4. The company's market cap stands at $81.3 million. </li>
<li><strong>Everus Construction Group</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECG#NYSE">ECG</a>) stock rose 19.57% to $61.48. The company's market cap stands at $3.1 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li><strong>Singularity Future Tech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGLY#NASDAQ">SGLY</a>) shares moved upwards by 16.86% to $0.95. The market value of their outstanding shares is at $3.9 million. </li>
<li><strong>Virgin Galactic Hldgs</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) shares rose 15.96% to $3.6. The market value of their outstanding shares is at $146.7 million. </li>
<li><strong>Primega Group Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGHL#NASDAQ">PGHL</a>) stock increased by 14.99% to $0.58. The company's market cap stands at $15.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>High-Trend International</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>) stock fell 66.9% to $0.48 during Wednesday's regular session. The company's market cap stands at $57.6 million. </li>
<li><strong>Ming Shing Group Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSW#NASDAQ">MSW</a>) shares fell 23.75% to $4.85. The company's market cap stands at $62.9 million. </li>
<li><strong>Nuvve Holding</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) stock decreased by 21.38% to $1.14. The company's market cap stands at $3.4 million. </li>
<li><strong>WANG &amp; LEE Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) shares declined by 19.96% to $0.25. The company's market cap stands at $5.3 million. </li>
<li><strong>Earlyworks Co</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELWS#NASDAQ">ELWS</a>) stock decreased by 19.88% to $2.0. The market value of their outstanding shares is at $6.0 million. </li>
<li><strong>Hyliion Holdings</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/HYLN#AMEX">HYLN</a>) shares decreased by 17.54% to $1.57. The market value of their outstanding shares is at $275.3 million. The company's, Q1 earnings came out yesterday.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ELWS

HTCO

HYLN

MCRP

NVVE

PGHL

SGLY

SPCE

SWVL

WLGS

12 Industrials Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li><strong>GCT Semiconductor Hldgs</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCTS#NYSE">GCTS</a>) shares increased by 34.8% to $2.27 during Wednesday's regular session. The market value of their outstanding shares is at $109.2 million. As per the press release, Q1 earnings came out today. </li>
<li><strong>Rigetti Computing</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) shares increased by 19.36% to $11.78. The market value of their outstanding shares is at $3.3 billion. As per the press release, Q1 earnings came out 2 days ago. </li>
<li><strong>Datavault AI</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVLT#NASDAQ">DVLT</a>) shares increased by 17.45% to $0.86. The company's market cap stands at $52.5 million. </li>
<li><strong>Super Micro Computer</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) stock increased by 17.2% to $45.58. The market value of their outstanding shares is at $27.2 billion. </li>
<li><strong>Yxt.Com Group Holding</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YXT#NASDAQ">YXT</a>) stock moved upwards by 15.51% to $1.0. The company's market cap stands at $60.0 million. </li>
<li><strong>NETSOL Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTWK#NASDAQ">NTWK</a>) stock moved upwards by 15.46% to $2.89. The market value of their outstanding shares is at $33.8 million. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Gryphon Digital Mining</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) stock decreased by 33.5% to $0.85 during Wednesday's regular session. The market value of their outstanding shares is at $59.0 million. </li>
<li><strong>X3 Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) shares decreased by 32.23% to $1.43. The market value of their outstanding shares is at $19.6 million. </li>
<li><strong>Endava</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAVA#NYSE">DAVA</a>) stock declined by 30.46% to $14.89. The market value of their outstanding shares is at $885.2 million. As per the press release, Q3 earnings came out today. </li>
<li><strong>Next Technology Holding</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) shares decreased by 29.19% to $1.99. The market value of their outstanding shares is at $13.8 million. The company's, Q1 earnings came out 3 days ago. </li>
<li><strong>LeddarTech Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) stock declined by 18.55% to $0.61. The company's market cap stands at $22.9 million. As per the news, the Q2 earnings report came out today. </li>
<li><strong>SmartKem</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTK#NASDAQ">SMTK</a>) stock declined by 17.42% to $1.66. The market value of their outstanding shares is at $6.0 million. As per the news, the Q1 earnings report came out yesterday.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


DAVA

DVLT

GCTS

GRYP

LDTC

NTWK

Next Technology Holding Inc. - Ordinary Shares

NXTT

RGTI

SMCI

SMTK

XTKG

12 Information Technology Stocks Moving In Wednesday's Intraday Session

<p><strong>American Eagle Outfitters Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) issued a profit warning and withdrew its full-year 2025 <a href="https://www.benzinga.com/quote/AEO/earnings">guidance on Tuesday</a>.</p>
<p>The retailer said it expects first-quarter revenue of $1.1 billion, a 5% decline from the prior year. Comparable sales are projected to be down around 3%, with the American Eagle brand down 2% and the Aerie brand down 4%. The company said it anticipates an operating loss of approximately $85 million, or $68 million on an adjusted basis.</p>
<p>American Eagle withdrew its full-year guidance due to broader macroeconomic uncertainty. While American Eagle said it entered the second quarter with better inventory positioning, the company is still actively reviewing its forward strategy and product performance.</p>
<p>American Eagle shares fell 4.8% to trade at $12.11 on Wednesday.</p>
<p>These analysts made changes to their price targets on American Eagle following the announcement.</p>
<ul class="wp-block-list">
<li>BMO Capital analyst Simeon Siegel maintained American Eagle Outfitters with a Market Perform and lowered the price target from $15 to $11.</li>
<li>JP Morgan analyst Matthew Boss maintained the stock with a Neutral and cut the price target from $10 to $9.</li>
</ul>
<p><strong>Considering buying AEO stock? Here&#8217;s what analysts think:</strong> </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="609" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14130434/image-167-1024x609.png" alt="" class="wp-image-915393" style="width:661px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14130434/image-167-1024x609.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14130434/image-167-300x178.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14130434/image-167-768x456.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14130434/image-167.png 1097w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read This Next: </strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45403847/coinbase-to-rally-around-17-here-are-10-top-analyst-forecasts-for-wednesday">Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday</a></strong> </li>
</ul>
<p>Photo via Shutterstock</p>


Guidance

Markets

Trading Ideas

These Analysts Slash Their Forecasts On American Eagle Outfitters

<p>HC Wainwright &amp; Co.  analyst Swayampakula Ramakanth   downgrades Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) from Buy to Neutral.</p>


Downgrades

AFMD

HC Wainwright & Co. Downgrades Affimed to Neutral

<p>JP Morgan  analyst Robbie Marcus   maintains NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) with a Overweight and raises the price target from $14 to $16.</p>


NPCE

JP Morgan Maintains Overweight on NeuroPace, Raises Price Target to $16

<p>Data Storage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTST#NASDAQ">DTST</a>) will release its quarterly earnings report on Thursday, 2025-05-15. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Data Storage to report an <strong>earnings per share</strong> (EPS) of $0.10.</p>
<p>The market awaits Data Storage's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings Track Record</h3>
<p>During the last quarter, the company reported an EPS beat by $0.01, leading to a 1.1% increase in the share price on the subsequent day.</p>
<p>Here's a look at Data Storage's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.03</td>
<td>0.05</td>
<td>0.03</td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.04</td>
<td>0.02</td>
<td>-0.04</td>
<td>0.05</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-4.0%</td>
<td>1.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Stock Performance</h3>
<p>Shares of Data Storage were trading at $4.0925 as of May 13. Over the last 52-week period, shares are down 35.42%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/DTST/earnings"><strong>To track all earnings releases for Data Storage visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


DTST

Data Storage's Earnings: A Preview

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>IBM</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with IBM, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 17 options trades for IBM.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 23% bullish and 64%, bearish.</p>
<p>Out of all of the options we uncovered, 16 are puts, for a total amount of $961,274, and there was 1 call, for a total amount of $28,960.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $200.0 to $260.0 for IBM over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in IBM's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to IBM's substantial trades, within a strike price spectrum from $200.0 to $260.0 over the preceding 30 days.</p>
<h3>IBM 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747242143_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>IBM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$13.5</td>
<td>$13.45</td>
<td>$13.5</td>
<td>$255.00</td>
<td>$130.8K</td>
<td align="right">45</td>
<td>3.0K</td>
</tr>
<tr>
<td>IBM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$13.5</td>
<td>$13.45</td>
<td>$13.53</td>
<td>$255.00</td>
<td>$98.4K</td>
<td align="right">45</td>
<td>3.0K</td>
</tr>
<tr>
<td>IBM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$13.4</td>
<td>$13.35</td>
<td>$13.4</td>
<td>$255.00</td>
<td>$93.6K</td>
<td align="right">45</td>
<td>2.3K</td>
</tr>
<tr>
<td>IBM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$13.4</td>
<td>$13.1</td>
<td>$13.4</td>
<td>$255.00</td>
<td>$93.4K</td>
<td align="right">45</td>
<td>2.3K</td>
</tr>
<tr>
<td>IBM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$13.5</td>
<td>$13.45</td>
<td>$13.52</td>
<td>$255.00</td>
<td>$93.2K</td>
<td align="right">45</td>
<td>3.0K</td>
</tr>
</tbody>
</table>
</p>
<h3>About IBM</h3>
<p>IBM looks to be a part of every aspect of an enterprise's IT needs. The company primarily sells software, IT services, consulting, and hardware. IBM operates in 175 countries and employs approximately 300,000 people. The company has a robust roster of business partners to service its clients, which include 95% of all Fortune 500 companies. Primary products include its mainframes, Red Hat software, transaction processing software, and IT consulting.</p>
<h3>IBM's Current Market Status</h3>
<ul>
<li>With a volume of 1,470,659, the price of IBM is down -0.67% at $256.85. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 70 days.</li>
</ul>
<h3>What The Experts Say On IBM</h3>
<p>Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $250.75.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Wedbush has revised its rating downward to Outperform, adjusting the price target to $300.<br />
&#x2A; Reflecting concerns, an analyst from Wedbush lowers its rating to Outperform with a new price target of $300.<br />
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on IBM, maintaining a target price of $233.<br />
&#x2A; An analyst from UBS has decided to maintain their Sell rating on IBM, which currently sits at a price target of $170. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for IBM, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Decoding IBM's Options Activity: What's the Big Picture?

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Walmart</strong>.</p>
<p>Looking at options history for Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) we detected 25 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 52% of the investors opened trades with bullish expectations and 36% with bearish.</p>
<p>From the overall spotted trades, 16 are puts, for a total amount of $1,550,164 and 9, calls, for a total amount of $477,887.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $85.0 and $102.0 for Walmart, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Walmart's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Walmart's significant trades, within a strike price range of $85.0 to $102.0, over the past month.</p>
<h3>Walmart 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747242138_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>WMT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$3.25</td>
<td>$3.15</td>
<td>$3.15</td>
<td>$85.00</td>
<td>$504.0K</td>
<td>5.1K</td>
<td>1.6K</td>
</tr>
<tr>
<td>WMT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$2.69</td>
<td>$2.6</td>
<td>$2.62</td>
<td>$95.00</td>
<td>$262.5K</td>
<td>5.8K</td>
<td>1.1K</td>
</tr>
<tr>
<td>WMT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$0.8</td>
<td>$0.77</td>
<td>$0.78</td>
<td>$92.50</td>
<td>$236.2K</td>
<td>5.2K</td>
<td>3.4K</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$11.85</td>
<td>$11.75</td>
<td>$11.75</td>
<td>$92.50</td>
<td>$96.3K</td>
<td>1.8K</td>
<td>85</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$1.63</td>
<td>$1.61</td>
<td>$1.63</td>
<td>$98.00</td>
<td>$80.1K</td>
<td>4.3K</td>
<td>536</td>
</tr>
</tbody>
</table>
</p>
<h3>About Walmart</h3>
<p>Walmart serves as a leading retailer in the United States, with its strategy predicated on superior operating efficiency and offering the lowest priced goods to consumers to drive robust store traffic and product turnover. Walmart augmented its low-price business strategy by offering a convenient one-stop shopping destination with the opening of its first supercenter in 1988.Today, Walmart operates over 4,600 stores in the United States (5,200 including Sam's Club) and over 10,000 locations globally. Walmart generated over $460 billion in domestic namesake sales in fiscal 2025, with Sam's Club contributing another $90 billion to the company's top line. Internationally, Walmart generated $120 billion in sales. The retailer serves around 270 million customers globally each week.</p>
<p>Having examined the options trading patterns of Walmart, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Walmart</h3>
<ul>
<li>Trading volume stands at 11,572,126, with WMT's price up by 0.67%, positioned at $96.52.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 1 days.</li>
</ul>
<h3>Professional Analyst Ratings for Walmart</h3>
<p>A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $108.5.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Telsey Advisory Group has decided to maintain their Outperform rating on Walmart, which currently sits at a price target of $115.<br />
&#x2A; An analyst from Truist Securities persists with their Buy rating on Walmart, maintaining a target price of $107.<br />
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $102.<br />
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Walmart with a target price of $110. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Walmart, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Walmart's Options Frenzy: What You Need to Know

<p>Deep-pocketed investors have adopted a bearish approach towards Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ALAB usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 24 extraordinary options activities for Astera Labs. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 29% leaning bullish and 54% bearish. Among these notable options, 3 are puts, totaling $131,480, and 21 are calls, amounting to $1,430,697.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $40.0 to $145.0 for Astera Labs over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Astera Labs options trades today is 493.56 with a total volume of 5,272.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Astera Labs's big money trades within a strike price range of $40.0 to $145.0 over the last 30 days.</p>
<h3>Astera Labs Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747242132_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$11.9</td>
<td>$11.4</td>
<td>$11.4</td>
<td>$100.00</td>
<td>$285.0K</td>
<td>417</td>
<td align="right">256</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$28.6</td>
<td>$28.0</td>
<td>$28.0</td>
<td>$77.50</td>
<td>$280.0K</td>
<td>939</td>
<td align="right">100</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$22.2</td>
<td>$21.4</td>
<td>$21.44</td>
<td>$70.00</td>
<td>$107.2K</td>
<td>1.3K</td>
<td align="right">51</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/23/25</td>
<td>$4.0</td>
<td>$3.8</td>
<td>$4.0</td>
<td>$90.00</td>
<td>$78.4K</td>
<td>375</td>
<td align="right">26</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.8</td>
<td>$5.7</td>
<td>$5.7</td>
<td>$145.00</td>
<td>$76.3K</td>
<td>542</td>
<td align="right">139</td>
</tr>
</tbody>
</table>
</p>
<h3>About Astera Labs</h3>
<p>Astera Labs Inc designs and delivers semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform integrates semiconductor technology, microcontrollers, sensors, and software to enhance performance, scalability, and data management. The company offers products such as integrated circuits (ICs), boards, and modules, catering to hyperscalers and system OEMs. The company's solutions focus on data, network, and memory management in AI-driven platforms.</p>
<p>Having examined the options trading patterns of Astera Labs, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Astera Labs Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 3,624,535, the ALAB's price is up by 3.42%, now at $90.76. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 103 days.</li>
</ul>
<h3>What The Experts Say On Astera Labs</h3>
<p>In the last month, 4 experts released ratings on this stock with an average target price of $93.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Needham has decided to maintain their Buy rating on Astera Labs, which currently sits at a price target of $100.<br />
&#x2A; Showing optimism, an analyst from Morgan Stanley upgrades its rating to Overweight with a revised price target of $99.<br />
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Astera Labs with a target price of $100.<br />
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Astera Labs, which currently sits at a price target of $75. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Astera Labs options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


ALAB

This Is What Whales Are Betting On Astera Labs

Health Care

Press Releases

General

Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium

Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit

Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia

Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland

Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®

Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results

Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis

Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results

ARTL

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Akanda

CNS Pharma

Enveric Biosciences

Evoke Pharma

Eyenovia

Jaguar Health

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharma

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

SenesTech

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

TNF Pharmaceuticals

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

cbdMD

D. Boral Capital

HC Wainwright & Co.

EF Hutton

Ladenburg Thalmann

Screenshot 2024-04-30 at 10.58.41 PM

Biotech

Interview

&#34;Brand New Science&#34; - This Biotech Is Entering Clinical Studies With What It Says Is Novel Science No One Else Has

Comments

Artelo Biosciences

Intérêt court

Artelo Biosciences (NASDAQ:ARTL) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL